Register entry
Boehringer Ingelheim Promeco S.A. de C.V.
- Registered sites
- 1
- Drug products
- 3
- Live patents
- 0
- Countries
- 1
- Base
- Mexico
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingLabellingFinished drug manufacturePackagingRelabellingRepackaging
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Boehringer Ingelheim Promeco S.A. de C.V. | Mexico CityMexico | Analytical testing, Labelling, Finished drug manufacture, Packaging, Relabelling, Repackaging | 1000183111 |
Catalogue
Marketed products
3Showing 3 of 3.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | Linsgliptin | TABLET | DRUG FOR FURTHER PROCESSING |
| - | empagliflozin | TABLET | DRUG FOR FURTHER PROCESSING |
| - | empagliflozin | TABLET | DRUG FOR FURTHER PROCESSING |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.